Skin Analytics

• 17/04/2025
• Series B
• $19,833,225

We’re working for a world where no one dies from skin cancer by deploying our AI medical device, DERM, to create the world’s most advanced skin cancer pathways.

Skin Analytics are proud to work with NHS dermatology teams to deploy AI powered skin cancer pathways.

Our pathways enable NHS organisations to discharge benign lesions earlier in the pathway and therefore tackle backlog, free up out-patient delays and crucially, reserve limited dermatology capacity to prioritise patients with skin cancer by focusing on providing potentially life-saving treatment.

Some things we’re a little bit proud of:

🚀We’ve deployed with 18 NHS partners across primary and secondary care since 2020

🥇We’re the first and only AI skin cancer pathway within the NHS

✅DERM is the only Class IIa UKCA marked and Class III CE marked AI as a Medical Device for skin cancer

🤯DERM is used in pathways that have seen over 135,000 NHS patients and identified more than 13,000 cancers

💪We’ve helped NHS organisations avoid up to 95% of face-to-face appointments in secondary care

🤳We provide Bupa and Vitality's remote skin assessment service

❤️Everything we do is in pursuit of better patients outcomes that are sustainable for health systems, globally

---

---